Loading
Countries buying radiotherapy machines one at a time pay high prices and get poor service. A single global buyer negotiating for dozens of machines a year could cut prices and demand long-term support.
Gavi and the Global Fund demonstrated that aggregated demand and multi-year volume guarantees lower prices, stabilise supply, and shape products. Radiotherapy has no equivalent: each ministry negotiates alone, with limited technical capacity, and often receives a machine without a bunker, staff, or service plan. A pooled purchaser (hosted, for instance, alongside the IAEA's Rays of Hope) would set standard specifications, bundle service and training, and publish prices.
Shares Elekta, Varian (Siemens Healthineers), Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
Shares Elekta, Varian (Siemens Healthineers).
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares Elekta, Varian (Siemens Healthineers), Most of the world has almost no cancer care.
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Most of the world has almost no cancer care.